Trial Profile
Phase II Trial of FavId (Patient-Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive FavId on Study FavId-06.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Mitumprotimut T (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 16 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 Dec 2007 The expected completion date for this trial is 1 Jun 2011.
- 01 Apr 2007 New trial centre added.